జర్నల్ ఆఫ్ డయాబెటిస్ అండ్ క్లినికల్ ప్రాక్టీస్

నైరూప్య

Short note on Heart Failure and Ventricular Function in Patients with Type 2 Diabetes

John JV

It is to study the sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients with heart failure and reduced ejection fraction Many patients with type 2 diabetes mellitus have heart failure and it is important to know about the safety of new treatments for diabetes in these individuals Compared with placebo, vildagliptin had no major effect on LVEF but did lead to an increase in left ventricular volumes, the cause and clinical significance of which is unknown.